<DOC>
	<DOCNO>NCT00087711</DOCNO>
	<brief_summary>This study randomize Phase 3 study compare pemetrexed cisplatin combination gemcitabine cisplatin treatment Non Small Cell Lung Cancer ( NCSLC ) . Gemcitabine plus cisplatin currently standard care NSCLC . It think pemetrexed plus cisplatin may effective may fewer side effect standard care .</brief_summary>
	<brief_title>A Randomized Phase 3 Trial Pemetrexed Cisplatin Versus Gemcitabine Cisplatin Patients With Locally Advanced Metastatic Non Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Diagnosis NSCLC Stage IIIB amenable curative treatment Stage IV . No prior chemotherapy lung cancer . Patients must least one unidimensionally measurable lesion . Prior radiation therapy le 25 % bone marrow , whole pelvis allow . Radiation must complete least 4 week prior study enrollment . Treatment drug within last 30 day receive regulatory approval . Serious cardiac condition . Serious medical disorder addition NSCLC would make difficult patient complete study . Inability unwillingness take folic acid Vitamin B12 supplementation . Presence fluid retention control drainage .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>